Shilpa Medicare Receives Eight FDA Observations Following Ten-Day Inspection at Jadcherla Manufacturing Facility
核心洞察
Shilpa Medicare's Unit IV facility in Jadcherla, Telangana completed a ten-day USFDA (搜索) inspection on November 21, 2025, receiving eight observations on FDA Form 483.
The manufacturing facility produces sterile injectables, oral tablets, and capsules for global markets, with US sales representing less than 1% of total business in H1 FY25-26.
None of the eight inspectional observations were categorized as repeat violations, and the facility maintains approvals from major international regulators including EMA, Health Canada, and TGA Australia.
Shilpa Medicare Limited announced the completion of a USFDA (搜索) inspection at its Unit IV manufacturing facility in Jadcherla, Telangana, India, which concluded on November 21, 2025. The ten-day regulatory inspection resulted in the issuance of FDA Form 483 containing eight inspectional observations, with none classified as repeat violations.
Manufacturing Capabilities and Global Reach
The Jadcherla facility operates as a multi-product manufacturing site capable of producing, packaging, testing, storing and distributing sterile injectables, oral tablets and capsules. The facility serves multiple international markets, supplying products to the United States, Europe and other global regions.
Despite its global manufacturing scope, the facility's contribution to Shilpa Medicare's US business remains relatively modest. US sales of products manufactured at this plant represented less than 1% of the company's total business during the first half of fiscal year 2025-26, and less than 5% of total business for the full fiscal year 2024-25.
Regulatory Standing and International Approvals
The Unit IV facility maintains regulatory approvals from several major international health authorities. Current approvals include the European Medicines Agency (EMA) for European markets, Health Canada, Brazil's Anvisa, and Australia's Therapeutic Goods Administration (TGA).
Company Response to Inspection Findings
Shilpa Medicare has committed to providing a comprehensive response to all eight inspectional observations within the timeframe stipulated by the USFDA (搜索). The company's statement emphasized that none of the observations were categorized as repeat violations, potentially indicating that the issues identified represent new areas for improvement rather than persistent compliance challenges.
The completion of this inspection represents part of the ongoing regulatory oversight that pharmaceutical manufacturers face when supplying products to the US market, regardless of the relative size of their American business operations.